Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Liquid Biopsy Whole-Genome Sequencing Optimizes MRD Detection in DLBCL
April 13th 2024Using the newly created MAESTRO-Pool tool, whole genome sequencing revealed DNA that could be used to more effectively detect minimum residual disease (MRD) in patients who have diffuse large B-cell lymphoma (DLBCL).
Read More
Targeting MACC1 Offers Promising Therapeutic Strategy for PAH
April 10th 2024Positive responses seen following experiments involving metastasis-associated in colon cancer 1 (MACC1) indicate that the biomarker can be used to better diagnose and treat patients with pulmonary arterial hypertension (PAH).
Read More
Older Patients With DLBCL Face Poor Overall Survival, High Costs With R-GemOx Treatment
April 1st 2024Treatment with R-GemOx was associated with significant health care resource utilization, high costs surrounding treatment, and low overall survival in elderly patients with diffuse large B-cell lymphoma (DLBCL).
Read More
Venetoclax/Azacitidine Shows Promise for Relapse Prevention in High-Risk MDS and AML
March 9th 2024Venetoclax and azacitidine was found safe, but further randomized trials are needed to determine the full extent of the combination’s efficacy in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Read More
Treatment With iFRC and Ibrutinib Maintenance Led to Durable PFS in Patients With CLL
February 29th 2024In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable remission years after treatment.
Read More
Intravenous Nipocalimab Infusions Safe, Effective Against Autoantibody-Mediated Diseases
February 29th 2024After being found effective over longer durations with smaller doses, this study found that nipocalimab infusions resulted in a tolerable safety profile and remained effective even in shorter treatment periods and with larger doses.
Read More
Review Highlights Potential for Bispecific Antibodies in DLBCL
February 28th 2024Investigators are optimistic about bispecific antibodies (BsAbs) for patients with diffuse large B-cell lymphoma (DLBCL), especially the possibility of combining different BsAbs with distinct targets for stronger treatment outcomes.
Read More
Possible Increase in Prevalence of Alzheimer Disease Found in Patients With Myasthenia Gravis
February 6th 2024Investigators observed an increase in the prevalence of Alzheimer disease in patients with diagnosed myasthenia gravis (MG), which indicates that MG is an independent risk factor for AD.
Read More